Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Neoplasms 6Ovarian Neoplasms 3Uterine Cervical Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Patients With Any Advanced Solid Tumors 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Genital Neoplasms, Female 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Cisplatin 27pembrolizumab 21Brachytherapy 16Radiotherapy 14Carboplatin 10Radiation 8Paclitaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Topotecan 6fludarabine 5atezolizumab 5Magnetic Resonance Spectroscopy 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Nivolumab 4Gemcitabine 4tremelimumab 3temsirolimus 3human papillomavirus vaccine, L1 type 16, 18 3aldesleukin 3Radiotherapy, Intensity-Modulated 3Papillomavirus Vaccines 3Ipilimumab 3Interleukin-2 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Docetaxel 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uterine Cervical Neoplasms × nintedanib × Clear all
NCT02835833 2018-07-10

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1 Completed
21 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡